Victory Capital Management Inc. Sells 6,180 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. trimmed its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 16.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,500 shares of the biotechnology company’s stock after selling 6,180 shares during the period. Victory Capital Management Inc. owned 0.11% of AnaptysBio worth $764,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ANAB. First Light Asset Management LLC raised its stake in shares of AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after buying an additional 446,372 shares during the last quarter. StemPoint Capital LP raised its stake in shares of AnaptysBio by 499.0% during the first quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after buying an additional 224,548 shares during the last quarter. Octagon Capital Advisors LP bought a new stake in shares of AnaptysBio during the fourth quarter worth approximately $2,570,000. Assenagon Asset Management S.A. raised its stake in shares of AnaptysBio by 38.2% during the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock worth $7,684,000 after buying an additional 84,795 shares during the last quarter. Finally, Great Point Partners LLC grew its holdings in AnaptysBio by 9.2% during the fourth quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after purchasing an additional 82,648 shares during the period.

AnaptysBio Stock Up 2.5 %

AnaptysBio stock opened at $38.48 on Friday. The stock has a market capitalization of $1.05 billion, a PE ratio of -6.27 and a beta of -0.29. AnaptysBio, Inc. has a twelve month low of $13.36 and a twelve month high of $41.31. The company has a 50 day moving average of $35.73 and a 200-day moving average of $27.86.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. Equities analysts anticipate that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now owns 11,618 shares of the company’s stock, valued at $406,630. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at $189,333.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the sale, the insider now directly owns 11,618 shares in the company, valued at $406,630. The disclosure for this sale can be found here. Insiders have sold a total of 32,440 shares of company stock valued at $1,193,831 over the last 90 days. 33.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ANAB. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a report on Wednesday, August 14th. Finally, Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.30.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.